PharmaCielo Ltd.
PCLOF
$0.03
-$0.01-17.21%
OTC PK
| 06/30/2025 | 09/30/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -8.31% | -45.28% | -45.28% | -80.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -8.31% | -45.28% | -45.28% | -80.15% |
| Cost of Revenue | -- | -31.06% | -39.30% | -39.30% | -41.23% |
| Gross Profit | -- | 102.78% | 18.68% | 18.68% | -346.24% |
| SG&A Expenses | -- | -40.38% | -40.75% | -40.75% | -41.79% |
| Depreciation & Amortization | -- | 149.75% | 243.91% | 243.91% | -12.28% |
| Other Operating Expenses | -- | 70.36% | 62.43% | 62.43% | 56.12% |
| Total Operating Expenses | -- | -32.58% | -37.18% | -37.18% | -40.78% |
| Operating Income | -- | 39.66% | 35.05% | 35.05% | 23.18% |
| Income Before Tax | -- | -8.51% | 8.59% | 8.59% | 2.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -8.51% | 8.59% | 8.59% | 2.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -8.51% | 8.59% | 8.59% | 2.44% |
| EBIT | -- | 39.66% | 35.05% | 35.05% | 23.18% |
| EBITDA | -- | 41.08% | 36.54% | 39.40% | 23.15% |
| EPS Basic | -- | -1.97% | 15.61% | 15.61% | 9.26% |
| Normalized Basic EPS | -- | 23.37% | 32.23% | 32.23% | 24.36% |
| EPS Diluted | -- | -1.97% | 15.61% | 15.61% | 9.26% |
| Normalized Diluted EPS | -- | 23.37% | 32.23% | 32.23% | 24.36% |
| Average Basic Shares Outstanding | -- | 6.51% | 8.39% | 8.39% | 7.37% |
| Average Diluted Shares Outstanding | -- | 6.51% | 8.39% | 8.39% | 7.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |